268 results
Page 4 of 14
8-K
EX-99.1
dgrxc8rvjgavij
5 Nov 20
Results of Operations and Financial Condition
8:40am
8-K
EX-99.1
stv0hcoor21m
28 Sep 20
Heron Therapeutics Receives European Commission Authorization for ZYNRELEFTM (HTX-011) for the Treatment of Postoperative Pain
8:41am
8-K
EX-99.1
0yta9donot8
16 Sep 20
Regulation FD Disclosure
8:40am
8-K
EX-99.1
tbn5iy w1j1ql
8 Sep 20
Heron Therapeutics Announces Successful Outcome of FDA Type A Meeting to Discuss HTX-011 for the Management of Postoperative Pain
8:41am
8-K
EX-99.1
i8p7 85ir1zwvsn
5 Aug 20
Results of Operations and Financial Condition
4:10pm
8-K
EX-99.1
uua2ss r2
24 Jul 20
Heron Therapeutics Receives Positive CHMP Opinion for ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain
8:40am
8-K
EX-99.1
ieqw5eis1ffy3efu2
16 Jul 20
Heron Therapeutics Announces Initiation of
8:40am
8-K
EX-99.1
2yac43azj6
29 Jun 20
Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain
4:06pm
8-K
EX-99.1
pxtxb0uf2sn7urhaya
4 Jun 20
Regulation FD Disclosure
9:14am
8-K
EX-99.1
tkbn8ad732n
18 May 20
Heron Therapeutics Announces Initiation of Phase 1b/2 Clinical Study of HTX-034 for the Treatment of Postoperative Pain
9:11am
8-K
EX-99.1
k2y8pca
6 May 20
Results of Operations and Financial Condition
9:10am
8-K
EX-99.1
yfn22aroy4c9lho77tkj
2 Mar 20
Results of Operations and Financial Condition
7:44am
8-K
EX-99.1
vygx5jld28w 3lombn
19 Feb 20
Heron Therapeutics Announces FDA Extension of Review Period for NDA for HTX-011 for the Management of Postoperative Pain
4:37pm
8-K
EX-99.1
3m9g9xf9zeoqduvjtn
13 Jan 20
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises
8:41am
8-K
EX-99.2
w5bd7q02gbt5sieoye7
13 Jan 20
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises
8:41am
8-K
EX-99.1
8nr8n0pdtrgb
16 Dec 19
Regulation FD Disclosure
4:15pm